Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 7—July 2016
Dispatch

Effective Chemical Inactivation of Ebola Virus

Elaine Haddock, Friederike Feldmann, and Heinz FeldmannComments to Author 
Author affiliations: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

Main Article

Table

Summary of methods and results for chemical inactivation of Ebola virus*

Inactivation method Reagent
volume Sample 
type† Inactivated 
sample
(final viral load) Contact
time Temp. Reagent
removal
process Result
(in vitro) Result
(in vivo)
Buffer AVL
560 µL Liquid virus 
stock 140 µL
(1.4 × 106 TCID50) 10 min 20°C Dialysis Pos
(1/9) Neg (0/15)
600 µL Liquid virus 
stock 100 µL
(106 TCID50) 10 min 20°C Dialysis Pos (1/9) Neg
(0/15)
560 µL Liquid virus 
stock 140 µL
(1.4 × 106 TCID50) Overnight 4°C Dialysis Neg
(0/9) ND
560 µL
Liquid virus 
stock
140 µL
(1.4 × 106 TCID50)
7 d
–80°C
Dialysis
Neg
(0/9)
ND
Buffer AVL
+ ethanol‡
560 µL Liquid virus 
stock 140 µL
(1.4 × 106 TCID50) 10 min +
20 min 20°C Dialysis Neg
(0/9) Neg
(0/15)
600 µL
Liquid virus 
stock
100 µL
(106 TCID50)
10 min +
20 min
20°C
Dialysis
Neg
(0/9)
Neg
(0/15)
Buffer RLT
600 µL Cell pellet 5 × 106 infected cells
(≈5 × 106 TCID50) 10 min 20°C Dialysis Pos (4/9) Pos (15/15)
800 µL
Cell pellet
5 × 106 infected cells
(≈5 × 106 TCID50)
10 min
20°C
Dialysis
Pos (6/9)
Pos
(14/15)
Buffer RLT + ethanol
600 µL Cell pellet 5 × 106 infected cells
(≈5 × 106 TCID50) 10 min +
20 min 20°C Dialysis Neg
(0/9) Neg
(0/15)
800 µL Cell pellet 5 × 106 infected cells
(≈5 × 106 TCID50) 10 min +
20 min 20°C Dialysis Neg
(0/9) Neg
(0/15)
600 µL
Tissue
30 mg
(≈3 × 105 TCID50)
10 min +
20 min
20°C
Dialysis
Neg
(0/9)
ND
TRIzol§
750 µL, 75% final Cell pellet in 250 µL 5 × 106 infected cells
(≈5 × 106 TCID50) 10 min 20°C Dialysis Neg
(0/9) ND
750 µL, 75% final Blood 250 µL
(≈2.5 × 105 TCID50) 10 min 20°C Dialysis Neg
(0/9) ND
1 mL
Tissue
50 mg
(≈5 × 105 TCID50)
10 min
20°C
Dialysis
Neg
(0/9)
ND
Formalin
750 µL, 7.5% final Cells, 250 µL 2.5 × 106 infected cells
(≈2.5 × 106 TCID50) Overnight 4°C Dialysis Neg
(0/9) Neg
(0/15)
10 mL, 10% final
Tissue
150 mg
(≈1.5x6 TCID50)
7 d or 30 d¶
4°C
Dialysis
Neg
(0/9)
ND
Glutaraldehyde
1.3 mL, 2% final Cells, 330 µL 3.3 × 106 infected cells
(≈3.3 × 106 TCID50) Overnight 4°C Dialysis Neg
(0/9) Neg
(0/15)
10 mL, 2% final
Tissue
150 mg
(≈1.5 × 106 TCID50)
7 d
4°C
Dialysis
Neg
(0/9)
ND
Paraformaldehyde
1.3 mL, 2% final Cells, 330 µL 3.3 × 106 infected cells
(≈3.3 × 106 TCID50) Overnight 4°C Dialysis Neg
(0/9) Neg
(0/15)
10 mL, 2% final
Tissue
150 mg
(≈1.5x6 TCID50)
7 d
4°C
Dialysis
Neg
(0/9)
ND
Heat#
NA Cells 1 mL, 1:10 dilution
(≈106 TCID50) 5 min 100°C NA Pos (3/3) ND
NA Cells 1 mL, 1:10 dilution
(≈106 TCID50) 10 min 100°C NA Neg
(0/9) ND
NA Cells 1 mL, 1:10 dilution
(≈106 TCID50) 5 min 120°C NA Neg
(0/9) ND
NA Cells 1 mL, 1:10 dilution
(≈106 TCID50) 10 min 120°C NA Neg
(0/9) ND
NA Liquid virus stock 1 mL, 1:10 dilution
(106 TCID50) 15 min 65°C or 70°C NA Pos (6/6) ND
NA
Liquid virus stock
1 mL, 1:10 dilution
(106 TCID50)
30 min
60°C or 65°C
NA
Pos (6/6)
ND
ELISA buffer
960 µL
Liquid virus stock
40 µL
(4 × 105 TCID50)
10 min
20°C
Detergent
column
Pos (2/9)
ND
Heat + ELISA buffer
960 µL Liquid virus stock 40 µL
(4 × 105 TCID50) 30 min 60°C Detergent
column Neg
(0/9) Neg
(0/15)
960 µL Liquid virus stock 40 µL
(4 × 105 TCID50) 15 min 65°C Detergent
column Neg
(0/9) ND
960 µL Liquid virus stock 40 µL
(4 × 105 TCID50) 30 min 65°C Detergent
column Neg
(0/9) ND
960 µL
Liquid virus stock
40 µL
(4 × 105 TCID50)
15 min
70°C
Detergent
column
Neg
(0/9)
ND
1% SDS, 5% 2-ME**
250 µL, 4× Cells, 250 µL 2.5 × 106 infected cells
(≈2.5 × 106 TCID50) 10 min 20°C Detergent
column Neg
(0/9) ND
250 µL, 4×
Tissue
150 mg
(≈1.5 × 106 TCID50)
10 min
20°C
Detergent
column
Neg
(0/9)
ND
1% SDS 250 µL, 4× Cells, 250 µL 2.5 × 106 infected cells
(≈2.5 × 106 TCID50) 10 min 20°C Detergent
column Neg
(0/9) ND

*DPBS, Dulbecco’s phosphate-buffered saline; NA, non-applicable; ND, not done; SDS, sodium dodecyl sulfate; TCID50, tissue culture infectious dose 50.
†Initial sample virus titers were as follows: liquid virus stock (1 × 107 TCID50/mL), infected cells (≈1 × 107 TCID50/mL, 1 × 107 cells/mL), blood (≈106 TCID50/mL), tissue (≈104 TCID50/mg). Infected cells (5 × 106 cells) were pelleted by centrifugation and lysed in test reagent (Buffer RLT; QIAGEN, Valencia, CA, USA), pelleted and resuspended in 250 μL DPBS before addition of test reagent (TRIzol; Life Technologies, Grand Island, NY, USA), or used directly in solution at the concentration and volume described in the table (fixative, heat, and SDS testing). Ebola virus–infected blood and liver tissue were collected from BALB/c mice infected with mouse-adapted Ebola virus at the height of infection, or from mock infected mice at a corresponding day.
‡Addition of ethanol: after contact time with Buffer AVL (QIAGEN, Valencia, CA, USA) or Buffer RLT, samples were transferred to a clean tube with 560 μL 100% ethanol (for AVL inactivation) or 600 μL 70% ethanol (for RLT inactivation) and allowed an additional 20 minutes contact time at 20°C.
§Although Spectra/Por Float-A-Lyzer G2 dialysis tubes (Spectrum Laboratories, Lawrenceville, GA, USA) were used for all other reagent removal by dialysis, Slide-A-Lyzer cassettes (Fisher Scientific, Pittsburgh, PA, USA) were used with TRIzol because the cassettes are more resistant to direct degradation by the reagent.
¶Tissue samples <1 cm3 were treated with a 7-day contact time, whereas samples >1 cm3 were treated with a 30-day contact time.
#Samples were boiled in an AccuBlock Digital Dry Bath (Sigma-Aldrich, St. Louis, MO, USA). All other heat treatments were carried out in a nonshaking water bath.
**4× SDS loading buffer contains 200 mmol/L Tris (pH 6.8), 4% SDS, 35% glycerol, 0.05% bromophenol blue and 20% 2-ME (added at the time of use). A combination of 250 μL 4× buffer, sample, and DPBS for a combined volume of 1 mL was tested; an appropriate volume of DPBS was substituted for 2-ME as necessary for testing of SDS as the single inactivating reagent.

Main Article

Page created: July 09, 2018
Page updated: July 09, 2018
Page reviewed: July 09, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external